• Lovastatin as a Precision Tool: Systems-Level Insights for C

  2026-06-10

  Explore the systems-level impact of Lovastatin as a potent HMG-CoA reductase inhibitor in cell biology research. This article uniquely unpacks its pleiotropic mechanisms, advanced assay applications, and direct protocol guidance, setting it apart from standard workflow articles.

• TCF25-Driven Lysosomal Adaptation and Cell Death in Glucose

  2026-06-10

  Ren et al. (2025) identify TCF25 as a key nutrient sensor that coordinates metabolic adaptation and cell death under glucose starvation by enhancing lysosomal acidification via V-ATPase. Their findings reveal how TCF25-mediated ferritinophagy links energy stress with cell death mechanisms, providing potential therapeutic targets for metabolic and ischemic disorders.

• Deferasirox Pharmacokinetics and Iron Chelation in Anemia Re

  2026-06-09

  The referenced review by Galanello et al. systematically evaluates Deferasirox (Exjade) as an oral iron chelator, detailing its pharmacokinetic profile, clinical efficacy, and safety in the management of transfusional iron overload across hematological disorders. These insights inform the rational design of laboratory protocols and translational studies aimed at advancing iron overload treatment research.

• α-Amanitin in Transcriptional Regulation: Protocols & Pitfal

  2026-06-09

  α-Amanitin stands out as a benchmark RNA polymerase II inhibitor, enabling researchers to dissect transcription-dependent processes with precision. This guide demystifies its applied workflows, highlights troubleshooting strategies, and translates recent innovations into actionable lab practice.

• Low-Affinity Blockade of N-Type Ca Channels by v-Agatoxin-IV

  2026-06-08

  This article examines the landmark study on the pharmacological properties of v-agatoxin-IVA and its selective and low-affinity blockade of neuronal N-type calcium channels. The findings clarify the molecular identity and functional diversity of high-threshold calcium channels in mammalian neurons, informing future neuroprotection and channel-selective research strategies.

• Deferasirox (Exjade): Pharmacokinetics and Iron Overload Res

  2026-06-08

  Galanello and colleagues provide a rigorous review of Deferasirox (Exjade) focusing on its pharmacokinetics, clinical efficacy, and safety for managing chronic iron overload in transfusion-dependent anemias. Their analysis establishes Deferasirox as a highly practical oral iron chelator with manageable risk, while highlighting ongoing challenges in optimizing iron burden monitoring and patient response.

• ROS-Degradable Lipid Nanoparticles for Tumor-Selective mRNA

  2026-06-07

  This study introduces a library of biodegradable lipid nanoparticles that leverage high intracellular ROS levels in cancer cells for selective mRNA delivery and gene expression. By screening and optimizing lipid structures, the authors achieved enhanced targeting of tumor cells, culminating in effective blockade of mutant RAS signaling and suppression of tumor growth.

• N1-Methyl-Pseudouridine-5'-Triphosphate in Advanced RNA Work

  2026-06-06

  Harness the unique benefits of N1-Methyl-Pseudouridine-5'-Triphosphate to boost RNA stability and translational efficiency in in vitro transcription and mRNA therapeutics. This guide delivers actionable workflows, troubleshooting insights, and lessons from cutting-edge retrotransposon research for reliable, high-yield RNA synthesis.

• BI 2536: Unraveling PLK1 Inhibition for Mitotic Checkpoint C

  2026-06-05

  Discover how BI 2536, a potent PLK1 inhibitor, advances the mechanistic understanding of mitotic checkpoint disassembly and apoptosis induction in cancer research. This article uniquely bridges cutting-edge reference data with practical assay guidance.

• MLKL Polymerization Drives Lysosomal Permeabilization in Nec

  2026-06-05

  Liu et al. reveal that MLKL polymerization at the lysosomal membrane is a direct trigger of lysosomal membrane permeabilization (LMP) during necroptosis, causing cytosolic release of active cathepsins—especially cathepsin B—which drive cell death. The study delineates a mechanistic link between necroptotic signaling and lysosomal rupture, providing a refined framework for targeting regulated cell death pathways in disease.

• Deferasirox (Exjade): Innovations in Iron Overload Managemen

  2026-06-04

  This review examines the pivotal findings of the FORMULARY REVIEW Deferasirox paper, focusing on the development and clinical validation of oral Deferasirox (Exjade) as a tridentate iron chelator for transfusional iron overload. The study demonstrates the compound’s efficacy and tolerability in chronic anemia contexts, marking a significant advance over traditional parenteral chelation strategies.

• TCF25 Modulates Lysosomal Cell Death Under Glucose Starvatio

  2026-06-04

  Ren et al. identify TCF25 as a nutrient sensor that enhances lysosomal acidification and drives cell fate decisions under glucose deprivation. These findings reveal new mechanistic connections between metabolic adaptation, autophagy, and lysosome-dependent cell death, highlighting TCF25 as a potential therapeutic target in metabolic and ischemic disorders.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-06-03

  Wang et al. uncover the METTL16-SENP3-LTF signaling axis as a key mechanism conferring ferroptosis resistance and promoting tumorigenesis in hepatocellular carcinoma (HCC). Their integrated molecular and in vivo study highlights the axis as a promising target for sensitizing HCC cells to ferroptosis, with implications for new cancer treatment strategies using iron chelation.

• Resibufogenin Inhibits NLRP3 to Reduce Atherosclerosis in Mi

  2026-06-03

  This study demonstrates that resibufogenin (RBG) directly blocks NLRP3 inflammasome assembly, leading to reduced inflammation and atherosclerotic plaque formation in ApoE-/- mice. The findings offer mechanistic insight into RBG as a potential therapeutic for cardiovascular disease and highlight advanced immunodetection tools relevant to translational research.

• Gepotidacin: Mechanistic Insight & Strategy for Translationa

  2026-06-02

  This thought-leadership article unpacks Gepotidacin’s (GSK2140944) distinctive mechanism as a triazaacenaphthylene bacterial type II topoisomerase inhibitor, guiding translational researchers through its experimental utility, clinical promise, and the strategic imperatives for combating antibiotic resistance. Drawing on clinical studies and advanced laboratory applications, we highlight APExBIO’s Gepotidacin as a cornerstone for next-generation antibacterial research, moving beyond conventional product narratives.

16402 records 1/1094 page Next 12345 下5页 Last page